Dosing Nucleoside Therapy in Early-Onset TK2D and Managing Diarrhea

Dr. Hirano and Dr. Zolkipli-Cunningham use "Dosing Nucleoside Therapy in Early-Onset TK2D and Managing Diarrhea" to move from approval to bedside practice.

Dr. Hirano asks whether the therapy suits the four-year-old from Case 1. Dr. Zolkipli-Cunningham answers that there is no question. After confirmation, clinicians explain the option to parents, outline initiation, and stress the need to remain on treatment. The drug is oral and can be given through a G-tube. It is taken three times daily, spaced over roughly six hours with about two hours between doses.

Dosing is weight-based. Clinicians escalate from 260 mg/kg per day to 520 mg/kg per day, with a target of 800 mg/kg per day of the two agents combined, assessing tolerability between steps. She cites monitoring for gastrointestinal effects, particularly diarrhea and vomiting, and for liver abnormalities. She considers this typical of many medicines. Diarrhea and vomiting can usually be managed, and few patients discontinue. Tolerability is assessed at each step, which is why close monitoring and family communication matter.

She shares a recent experience. A patient's diarrhea turned out to be related to osmotic, high-calorie G-tube feeds, whether bolus or overnight, and not to the drug. Changing the feed type, altering delivery, and spacing it out allowed the drug to be tolerated and continued.

Dr. Hirano asks how to manage diarrhea. Dr. Zolkipli-Cunningham says mild versus severe is subjective and depends on the patient and age, since young children cannot afford losses of calories and fluids. Mild to moderate diarrhea responds to standard prescription or over-the-counter antidiarrheals, ideally with gastroenterology input. She warns against attributing symptoms to the drug alone, because a family that perceives severe diarrhea may stop a therapy they would otherwise benefit from.

Up next, in "TK2D Treatment Safety: Dose Reduction, Diarrhea, and Elevated Transaminases," the experts review discontinuation and dose-reduction rates from the pooled safety data and explain how to interpret elevated transaminases.